A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
ZX-101A-202 is a Phase I, open-label, multicenter study, a single-agent dose-escalation and
dose-expansion study of ZX-101A. It is designed to evaluate the safety, tolerability,
pharmacokinetics, pharmacokinetics, efficacy and antitumor activity of ZX-101A in patients
with relapsed/refractory hematological malignancies.